Hormone receptor-positive (HR+) advanced breast cancer: Where we are now and next steps
Cost: FreeView Offer chevron_right
Activity Description / Statement of Need:
In this online, self-learning activity:
Over a quarter million women and almost 2,700 men in the U.S. are diagnosed with breast cancer each year, and it is the second leading cause of cancer death in women. The prognosis associated with breast has improved in the last few decades due in larger part to earlier detection. However, while detection at the loco-regional stage is associated with a five-year overall survival (OS) rate of 90%, patients with breast cancer that has progressed may expect five-year OS rates closer to 28%.
The goals of care in advanced breast cancer (ABC) include: palliation of symptoms, improvement of quality-of-life, and extension of survival. Hormone receptor positivity has traditionally conferred a better prognosis. In contrast, the presence the human epidermal growth factor receptor 2 (HER2), which is associated with a more negative prognosis. A wide array of advances in care – approved and investigational – have been or are being developed for HR+ ABC in recent years. This activity has been designed to bring healthcare professionals’ knowledge of the rationale behind treatment of HR+ ABC up to date and improve their competence and performance in treating it.
Medical oncologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with breast cancer.